Shares of Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) have received a consensus rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $4.50.

NVCN has been the subject of a number of research analyst reports. ValuEngine cut shares of Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Zacks Investment Research raised shares of Neovasc Inc (US) from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a report on Wednesday, October 11th. Finally, Canaccord Genuity initiated coverage on shares of Neovasc Inc (US) in a report on Friday. They set a “buy” rating for the company.

A hedge fund recently bought a new stake in Neovasc Inc (US) stock. Virtu KCG Holdings LLC bought a new position in shares of Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 108,132 shares of the medical equipment provider’s stock, valued at approximately $149,000. Virtu KCG Holdings LLC owned about 0.14% of Neovasc Inc (US) at the end of the most recent reporting period. Institutional investors own 19.04% of the company’s stock.

Neovasc Inc (NASDAQ NVCN) traded down $0.01 during midday trading on Friday, hitting $0.52. 977,500 shares of the company’s stock were exchanged, compared to its average volume of 815,925. The stock has a market capitalization of $41.91, a PE ratio of 2.17 and a beta of -0.08. Neovasc Inc has a fifty-two week low of $0.50 and a fifty-two week high of $2.12.

Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) last posted its quarterly earnings results on Tuesday, November 14th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.04). Neovasc Inc (US) had a negative return on equity of 85.81% and a net margin of 268.35%. analysts expect that Neovasc Inc will post -0.22 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://theolympiareport.com/2018/01/19/neovasc-inc-us-nvcn-given-average-rating-of-buy-by-brokerages.html.

About Neovasc Inc (US)

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with MarketBeat.com's FREE daily email newsletter.